Skip to main content

Table 7 Survival of PSP cases by NAT2 phenotype

From: Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study

NAT2 Phenotype Median(Min, Max) Mean(SD) p-values
Age at Onset    
Rapid 68.5(51,85) 68.5(8.5) > 0.05
Intermediate 68(41,89) 68.1(8.6) > 0.05
Slow 68(47,90) 67.9(8.1) --
Age at Death    
Rapid 75.5(58,89) 75.3(7.9) > 0.05
Intermediate 76(44,98) 75.3(8.3) > 0.05
Slow 76(53,95) 75.4(7.9) --
Disease Duration (yrs.)    
Rapida 6(2,12) 6.6(2.2) 0.025, 0.078, 0.028
Intermediateb 7(2,31) 7.4(3.6) 0.675
Slow 7(0,27) 7.5(3.3) --
  1. Pairwise comparisons of age at onset, age at death, and disease duration by NAT2 phenotype (t-test with unequal variances). ap-values = rapid vs. slow, rapid vs. intermediate, rapid vs. slow + intermediate, respectively. bp-value = slow vs. intermediate. Overall p-values from Wilcoxon rank sum tests were all > 0.1